Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial

NCT: NCT06719947 · RECRUITING

NCT IDNCT06719947
StatusRECRUITING
Start Date2025-11-28
Completion2028-09-01
SponsorUniversidade Federal do Rio Grande do Norte (OTHER)
First posted
Last updated

Brief Summary

Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality. Studies suggest that High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a technique for modulating motor cortical hyperexcitability. However, evidence on the use of HD-tDCS as a neuromodulator of the diaphragmatic motor cortex in people with ALS is inconclusive.

Frequently Asked Questions

What is HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial?

HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial is a clinical trial registered under NCT06719947. Current status: RECRUITING.

What is the status of NCT06719947?

The current status of NCT06719947 (HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial) is: RECRUITING.

When did HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial start?

HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial started on 2025-11-28.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.